Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369050 | 0.89 | LMNA (0.50) | LMNASMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL5503597 | 0.82 | LMNA (0.45) | LMNASMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL7600529 | 0.81 | LMNA (0.41) | LMNASMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL11677163 | 0.80 | LMNA (0.43) | LMNASMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL11553081 | 0.80 | LMNA (0.43) | LMNASMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL1364726 | 0.78 | LMNA (0.42) | LMNASMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL5503600 | 0.78 | LMNA (0.42) | LMNASMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL7937629 | 0.76 | LMNA (0.41) | LMNASMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL10938009 | 0.75 | TSHR (0.52) | LMNASMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL11700624 | 0.75 | LMNA (0.39) | LMNASMN1; SMN2TSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2921499-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
| EP-0135587-B2 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | SYNGENE INC (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6248916-B1 | WATER SOLUBLE, STRAIGHT CHAIN BORON-RICH OLIGOPHOSPHATE WHICH COMPRISES AN ORDERED PLURALITY OF CARBORANE MONOMER UNITS HAVING TWO HYDROXYL GROUPS ATTACHED THERETO BEING LINKED BY THE HYDROXYL GROUPS TO PHOSPHATE UNITS | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-06-19 | — | — | US | disclosed |
| US-5856551-A | REACTING DIHYDROXYCARBORANE WITH PHOSPHORUS COUPLING AGENT;THEN ALCOHOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-01-05 | — | — | US | disclosed |
| US-5817786-A | Single-stranded labelled oligonucleotides of preselected sequences | MOLECULAR BIOSYSTEMS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5668266-A | Synthesis of single-stranded labelled oligonucleotides of preselected sequence | SYNGENE, INC. (US) | 1997-09-16 | — | — | US | disclosed |
| WO-1989005853-A1 | NUCLEIC ACID CHELATE CONJUGATE AS THERAPEUTIC AND DIAGNOSTIC AGENTS | SYNTHETIC GENETICS (US) | 1989-06-29 | — | — | WO | disclosed |
| EP-0321548-A1 | NOVEL AMPHIPHILIC NUCLEIC ACID CONJUGATES | SYNTHETIC GENETICS (US) | 1989-06-28 | — | — | EP | disclosed |
| WO-1988009810-A1 | NOVEL AMPHIPHILIC NUCLEIC ACID CONJUGATES | SYNTHETIC GENETICS (US) | 1988-12-15 | — | — | WO | disclosed |
| EP-0135587-A4 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1986-04-02 | — | — | EP | disclosed |
| EP-0135587-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1985-04-03 | — | — | EP | disclosed |
| WO-1984003285-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | MOLECULAR BIOSYSTEMS INC (US) | 1984-08-30 | — | — | WO | disclosed |
| EP-0050841-B1 | FLUID BED PROCESS FOR PREPARING PHENYLPHOSPHONOUS DICHLORIDE | STAUFFER CHEMICAL COMPANY (US) | 1984-05-02 | — | — | EP | disclosed |
| US-4436673-A | BENZENE REACTED WITH PHOSPHORUS TRICHLORIDE | STAUFFER CHEMICAL COMPANY (US) | 1984-03-13 | — | — | US | disclosed |
| US-4409152-A | Continuous high pressure process for preparing phenylphosphonous dichloride | STAUFFER CHEMICAL COMPANY (US) | 1983-10-11 | — | — | US | disclosed |
| EP-0050841-A1 | Fluid bed process for preparing phenylphosphonous dichloride | STAUFFER CHEMICAL COMPANY (US) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | POLM, POLRMT, RNMT | LMNA 233/4885SMN1; SMN2 920/4885TSHR 495/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | LMNA 214/4885SMN1; SMN2 950/4885TSHR 551/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | LMNA 204/4885SMN1; SMN2 1165/4885TSHR 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.